Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that has spread to more than 70 countries worldwide since 2015. Despite active research, there are currently no licensed vaccines or therapeutics. We have previously reported the development of various adenoviral vectored vaccine candidates...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	López-Camacho, C, Kim, Y, Abbink, P, Larocca, R, Huiskonen, J, Barouch, D, Reyes-Sandoval, A
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	MDPI 2019

Παρόμοια τεκμήρια

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
ανά: César López-Camacho, κ.ά.
Έκδοση: (2019-11-01)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
ανά: Moorthy, V, κ.ά.
Έκδοση: (2003)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
ανά: Alharbi, N
Έκδοση: (2014)

Clinical development of Modified Vaccinia virus Ankara vaccines.
ανά: Gilbert, S
Έκδοση: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
ανά: Gilbert, S
Έκδοση: (2013)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
ανά: McConkey, S, κ.ά.
Έκδοση: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
ανά: Rosario, M, κ.ά.
Έκδοση: (2010)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
ανά: Schneider, J, κ.ά.
Έκδοση: (1998)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
ανά: L. F. Stovba, κ.ά.
Έκδοση: (2023-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
ανά: Olga Vladimirovna Orlova, κ.ά.
Έκδοση: (2022-09-01)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
ανά: Nereida Jiménez de Oya, κ.ά.
Έκδοση: (2022-03-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
ανά: López-Camacho, C, κ.ά.
Έκδοση: (2020)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
ανά: Alharbi, N, κ.ά.
Έκδοση: (2015)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
ανά: Naif Khalaf Alharbi, κ.ά.
Έκδοση: (2015-01-01)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
ανά: Lior Nave, κ.ά.
Έκδοση: (2023-08-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
ανά: Kaïdre Bendjama, κ.ά.
Έκδοση: (2017-09-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
ανά: Goepfert P, κ.ά.
Έκδοση: (2012-09-01)

Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial
ανά: Milligan, I, κ.ά.
Έκδοση: (2016)

Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial
ανά: Milligan, I, κ.ά.
Έκδοση: (2016)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
ανά: Mcshane, H, κ.ά.
Έκδοση: (2001)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
ανά: Behboudi, S, κ.ά.
Έκδοση: (2004)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
ανά: César López-Camacho, κ.ά.
Έκδοση: (2020-06-01)

Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
ανά: Valentina Mazzotta, κ.ά.
Έκδοση: (2024-12-01)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
ανά: Goonetilleke, N, κ.ά.
Έκδοση: (2003)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
ανά: Mingwang Shen, κ.ά.
Έκδοση: (2024-10-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
ανά: Gilbert, S, κ.ά.
Έκδοση: (1999)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
ανά: Juan García-Arriaza, κ.ά.
Έκδοση: (2021-08-01)

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
ανά: Jeffrey R Currier, κ.ά.
Έκδοση: (2010-11-01)

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
ανά: Sandhya Vasan, κ.ά.
Έκδοση: (2010-01-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
ανά: Hanke, T, κ.ά.
Έκδοση: (1998)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
ανά: Howles, S, κ.ά.
Έκδοση: (2010)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
ανά: Caroline Staib, κ.ά.
Έκδοση: (2003-04-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
ανά: Volker Sandig, κ.ά.
Έκδοση: (2013-11-01)

Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
ανά: Leonie Mayer, κ.ά.
Έκδοση: (2024-11-01)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
ανά: Flavia Chiuppesi, κ.ά.
Έκδοση: (2024-02-01)

The Efficacy of Disinfection on Modified Vaccinia Ankara and African Swine Fever Virus in Various Forest Soil Types
ανά: Franziska Tanneberger, κ.ά.
Έκδοση: (2021-10-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
ανά: Harriet L. Robinson, κ.ά.
Έκδοση: (2018-09-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
ανά: David A Garber, κ.ά.
Έκδοση: (2009-01-01)

Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
ανά: Leonie Mayer, κ.ά.
Έκδοση: (2024-12-01)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
ανά: C. Staib, κ.ά.
Έκδοση: (2000-06-01)